by mpzzqmvj | Nov 16, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH, CYTHW) (“Cyclo Therapeutics” of the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients...
by mpzzqmvj | Nov 16, 2021 | Press Releases
– Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s Disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying...
by mpzzqmvj | Nov 15, 2021 | Press Releases
Continued progress in lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo...
by mpzzqmvj | Nov 10, 2021 | Press Releases
Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16th at 11:00 AM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo...
by mpzzqmvj | Nov 2, 2021 | Press Releases
– Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer’s disease – Company continues to advance evaluation of Trappsol® Cyclo™ toward Phase 2 study in Alzheimer’s disease with...
